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Legal medicines and illegal drugs play a significant role in today’s society. The laboratory 
analysis of these substances is central not only in therapeutic monitoring but also in clinical 
and forensic toxicology, which aims to provide evidence-based information on the abuse and 
harmful effects of these substances. The rapid emergence of newly abused drugs known as 
new psychoactive substances (NPS) has challenged the conventional drug testing concept. 
On the European illicit drug market, approximately fifty new substances are identified each 
year, many of which are poorly characterized for their pharmacological effects or toxicity. 
Moreover, the lack of authentic primary reference standards (PRS) bottlenecks the 
development of analytical assays for NPS, which hinders both detection and toxicological 
evaluation of these drugs. 
High-resolution mass spectrometry (HRMS) has recently been applied to tentative 
identification of unknown compounds by targeting the precursor ions with high mass 
accuracy, resolution and speed. This capability has permitted a breakthrough in facile 
screening for suspected NPS, but until now, no practical method has been described for 
quantitative bioanalysis of NPS in the absence of PRS. In this thesis, a new analytical 
platform was developed and exploited for the simultaneous qualitative and quantitative 
analysis of NPS and metabolites without using PRS. In this platform, the gas 
chromatographic (GC) flow was divided between an atmospheric pressure chemical 
ionization - quadrupole time-of-flight mass spectrometer (APCI-QTOFMS) for tentative 
identification and a nitrogen chemiluminescence detector (NCD) for quantitative estimation 
based on the detector’s equimolar response to nitrogen-containing substances. Replacement 
of the ordinary electron ionization (EI) source with APCI was proven to be useful in 
substance identification by QTOFMS because it allowed the preservation of the precursor 
ion for tentative identification. The GC-APCI-QTOFMS tandem mass spectrometry 
(MS/MS) experiments using 29 NPS showed that all substances shared the same major 
fragments as in the commercial spectral library created by using liquid chromatography (LC) 
electrospray (ESI) MS/MS instrumentation. Consequently, these findings promote the 
usability of external soft-ionization compound libraries with the new GC-APCI-QTOFMS 
platform. The accuracy and precision of the N-equimolar quantification by GC-NCD were 
tested using several NPS in four separate studies using post-spiked sheep blood (n = 5), post-
mortem blood (n = 38) and urine (n = 3), and in seized powdery material (n = 28). The 
combined results from these studies, excluding the post-spiked samples, showed that NPS 
could be quantified with a grand mean accuracy of 91.7% and with a grand mean 
imprecision (CV) of 9.5% in the absence of PRS for compensating sample preparation and 
analysis. 
In conclusion, the GC-NCD-APCI-QTOFMS platform proved feasible for analyzing 
suspected nitrogen-containing drugs, such as stimulant-type NPS and metabolites, in 
situations where appropriate reference standards are not readily accessible. Simultaneous 
tentative identification by HRMS and quantitative estimation by NCD has unparalleled 





possibility for high-throughput retrospective identification and quantification is an additional 






Drug testing is one of the most commonly employed branches of analytical and forensic 
toxicology, used to provide clinical, supervisory or judicial evidence for potential substance 
abuse or poisoning. Analysis of drugs of abuse may help to answer questions such as: What 
was the cause of death? Was the person under the influence of alcohol or drugs? Was the 
victim drugged? What is the quantity and purity of seized illegal substances? On a 
population-scale, further analysis of forensic drug testing data can be used to study 
epidemiological patterns, such as the prevalence of drug use in the society, and link certain 
drugs with a higher incidence of toxicity. According to the basic principles of pharmacology 
and toxicology, the induced effect mediates through two interconnected factors: mechanism 
of action and quantity. Thereby the knowledge of the presence of a drug in the body is not 
alone sufficient to understand the magnitude of its effect in a given situation, although it 
may be sufficient for administrative sanctions. In forensic toxicology, quantitative analysis 
is employed to distinguish impairment from non-impairment in many types of 
investigations, such as driving under the influence or cause-of-death investigation. 
Over the past few decades, one of the most challenging problems in forensic 
toxicology has been the accelerated emergence of new psychoactive substances (NPS), 
which were formerly known as designer drugs. The United Nations Office on Drugs and 
Crime (UNODC) has defined NPS as “substances of abuse, either in a pure form or a 
preparation, that are not controlled by the 1961 Single Convention on Narcotic Drugs [1] or 
the 1971 Convention on Psychotropic Substances [2], but which may pose a public health 
threat” [3]. According to the EU Drug Markets Report 2019, the EU Early Warning System 
reported 172 new substances between years 2016-2018, with an approximal annual rate of 
57 NPS per year [4]. Attempts to legislatively control NPS have been slow since drug policy 
in most countries has been adapted from these UN treaties, which were not designed for 
facing numerous NPS. The legislative problems related to NPS are often characterized as a 
cat-and-mouse game, meaning that new substances appear as soon as established NPS are 
banned. Additionally, these substances’ hazardous effects are not well understood because 
comprehensive drug safety testing has not been carried out. Moreover, keeping up with the 
emerging trends is difficult because of fast production and a short lifetime of NPS.  
The analytical measurement of NPS is difficult, because certified primary reference 
standards (PRS) are often unavailable. In conventional drug analysis, a reference standard is 
needed to prove drug identity based on the unique chemical properties of a substance under 
defined experimental conditions, especially the retention time in chromatographic analysis 
and the fragmentation pattern in mass spectrometry (MS). In quantitative analysis, reference 
standards are used to construct a calibration curve. Rapid detection of NPS has been 
drastically facilitated by the advent of high-resolution mass spectrometry (HRMS) as a part 
of modern wide-scope screening methods, enabling simultaneous detection of various 
substances at a ng/mL level in complex biological samples, such as blood or urine [5, 6]. 
However, quantification using this instrumentation is problematic because the production of 
ions in the ion source is structure-dependent, and the signal response is highly unpredictable 
without proper reference standards [7, 8]. For this reason, clinical and forensic laboratories, 





especially for their metabolites. A rare but exciting approach is to apply the nitrogen 
chemiluminescence detector (NCD) to the quantitative estimation of nitrogen-containing 
drugs in the absence of PRS [9]. This detector possesses an equimolar response to nitrogen, 
and therefore, a suitable external nitrogen-containing calibrator can be used for quantitative 
calibration. Until now, drug analysis by NCD has been limited to liquid chromatography 
(LC) applications, however, gas chromatography (GC) could potentially be a more useful 
technique in the analysis of complex biological material due to its better chromatographic 
resolution. 
In this thesis, a new concept of combining HRMS with NCD for the analysis of NPS 
and metabolites without PRS is presented and elaborated. In the analytical platform studied, 
the GC flow is divided between an NCD for quantification and a quadrupole time-of-flight 
mass spectrometer (QTOFMS), equipped with an atmospheric pressure chemical ionization 
(APCI) source, for identification. This approach is anticipated to be feasible in NPS analysis, 
because most drugs and psychoactive substances contain nitrogen in their structure, and 
consequently the approach allows instant filtering of non-nitrogen compounds in complex 
samples. The studies included in this thesis explore the possibility of using the GC-NCD-
APCI-QTOFMS platform as an integral part of customary forensic applications, such as 
drug screening in biological specimens or purity analysis of seized drugs. In this context, the 
laboratory would be able to obtain quantitative information on new substances as soon as 
they become available on the illegal market via the Internet. 
 
 




2 REVIEW OF THE LITERATURE 
2.1 DRUG TOXICITY 
Consumption of psychoactive substances has been historically documented in the context of 
medical use (e.g., opium), in religious ceremonies (e.g., Amanita muscaria), and in socially 
acceptable products (e.g., alcohol and tobacco) [10]. Since the 20th century, the 
pharmaceutical industry has given rise to numerous new synthetic drugs that are available to 
today’s healthcare. At the same time, the prevalence of the abuse of prescription drugs and 
illicit drugs is increasing. In Finland for instance, drug-related mortality has almost doubled 
between 2000 and 2018 (from 2.6 to 4.7 deaths per 100 000 capita) [11].  
In some cases, even medicinal drug intake causes unintended adverse effects, and 
therefore healthcare professionals must choose appropriate medical treatment by balancing 
the benefits over the risks. According to the definition by the International Programme of 
Chemical Safety (IPCS), the risk can be defined as “the probability of an adverse effect in an 
organism, system, or (sub)population caused under specified circumstances by exposure to 
an agent.” [12]. Adverse effects and exposure can be studied by the examination of 
pharmacodynamic (what drug does to body) and pharmacokinetic (what body does to drugs) 
properties of a drug. The study of pharmacodynamics reveals the mechanisms of the 
therapeutic and adverse effects of a drug that take place by modulating the body’s 
endogenous machinery (i.e. potency, receptor selectivity, binding affinity, or type of 
agonism). In contrast, pharmacokinetic factors control the exposure to a drug at the site of 
action by various mechanisms (i.e. absorption, distribution, metabolism, excretion or protein 
binding) [13]. Consequently, the complexity of possible molecular interactions explains why 
drugs with similar molecular structures exhibit varying physicochemical properties that 
result in varying responses, such as the onset and duration of action, potency, adverse effects 
or even pharmacological response. Naloxone and morphine, for example, are structurally 
similar yet their action in the opioid receptors is reverse. 
There is a growing interest in conducting toxicological studies faster and more cost-
effectively by using a combination of in vitro tests, high-throughput analytical techniques 
and computational in silico methods [14]. In practice, examination of the drug structure-
function relationship allows rapid pharmacological classification of drugs, and modern in 
silico tools can use structural data to predict potential functional or toxicological signals at 
the early phase of drug development or toxicological assessment [15, 16]. Despite the 
undisputed benefits of structural prediction, the lengthy and resource-intensive safety testing 
of new drug candidates is still likely to remain in a central position in the assessment of 











2.1.1 ROLE OF QUANTITY IN TOXICITY AND FORENSIC ANALYSIS 
 
In his defense against accusations of treating patients with toxic mercury, Paracelsus, a 
famous Swiss physician and alchemist replied with a sentence that would later become a 
famous quote in toxicology: “What is there that is not poison, all things are poison and 
nothing (is) without poison. Solely the dose determines that a thing is not a poison” [17]. 
According to Paracelsus, treatment is only successful if the dose is neither too much nor too 
little. This idea has been well adapted in modern pharmacotherapy, where the dose-response 
relationship is carefully investigated to reduce the incidence of adverse effects. One widely 
used method to characterize a suitable dose has been the use of the therapeutic index, in 
which a range of doses is tested to observe both the minimum therapeutically effective dose 
and the dose that produces adverse effects [18]. A similar concept is used in the clinical 
practice known as the therapeutic drug monitoring (TDM), where physicians monitor the 
drug concentration levels of their patients at specific intervals to ensure that effective dose is 
given continuously with minimal adverse effects [19, 20].  
It is evident that drug concentrations should be measured from forensic samples (e.g., 
blood, urine or seized material) always when it is crucial to determine the magnitude of drug 
effect, impairment, or in the valuation of illicit drug seizures. In the light of the fact that 
quantitative assays are always more tedious, costly and time-consuming than identification 
alone, such analyses must provide additional value to forensic decision-making, some of 




























































































































































































































































































































































































































































































































































































































































2.1.2 DRUG METABOLITES 
 
Foreign molecules (xenobiotics) are eliminated mainly through urine and feces [33]. During 
the clearance many drugs are transformed into water-soluble metabolites, mostly in the liver, 
kidney and intestines [34]. The enzymatic reactions catalyzing drug transformation are 
divided into phase I (functionalization) and phase II (conjugation) reactions. In phase I, one 
or several separate reactions (e.g., oxidation, reduction, or hydrolysis) are required to reveal 
a functional group that is compatible to form a covalent bond with a polar endogenous 
conjugating agent (e.g., gluthathione or uridine diphosphate glucuronic acid) in phase II 
[34].  It is estimated that approximately three-quarters of the top 200 prescribed drugs in the 
US (in the year 2002) undergo a metabolic transformation in the human body, often by the 
catalytic action of the cytochrome P450 enzyme family [35]. As a result, unchanged drugs, 
drug metabolites, or a mixture of both are detectable in body fluids.  
Failure in drug metabolism can lead to unexpected toxicity due to accumulation or 
temporary increase or decrease of the drug concentration at its target location. It is now well 
established that drug metabolism is sensitive to many external and internal factors (e.g., 
genetic variation, age-specific expression of metabolic enzymes, cellular damage or 
modulation of metabolizing enzymes), which may expose drug therapy to risk [34, 36]. 
Particularly drug-drug interactions in polydrug use are commonly causing adverse effects or 
even fatal poisonings in geriatric patients and recreational drug users [13, 37, 38]. In some 
cases, metabolites themselves can induce acute or chronic toxicity (e.g., via depletion of the 
detoxification mechanisms) [39]. Furthermore, it is estimated that a reactive metabolite, 
rather than the parent drug itself, is responsible for most of the idiosyncratic adverse effects 
that are not necessarily detected in large clinical trials [40, 41]. In the 2000s, the safety 
testing of drug metabolites has gained increasingly more attention in pharmaceutical 
development. Much of the groundwork was laid in a paper by Baillie et al. (2002), 
suggesting that drug safety testing should include major human metabolites [42]. In this 
particular proposition, quantitative metabolite safety testing was suggested to be carried out 
if the metabolite is considered a “major metabolite” (>25% of drug’s total exposure), if it is 
an important active metabolite which is known to contribute to the pharmacological activity 
of its parent drug, or if a metabolite contains a structural alert for toxicity. Consequently, 
some of these suggestions were adapted in the official guidelines, such as by the European 
Medicines Agency (EMA 2013) and the US Food and Drug Administration (FDA 2020), 
where it is stated that major drug metabolites that contribute greater than 10% of drug’s 
exposure should be tested [43, 44].  
Metabolites are richly encountered in urine. Urine is easy to collect, and drugs in urine 
have generally a longer detection time-window compared to blood [45]. These features make 
urine an ideal specimen for qualitative forensic analysis, such as wide-scope drug screening. 
However, quantitative data obtained from urine analysis must be interpreted with caution, 
because absolute concentration values are largely influenced by changes in water content, 
pH, metabolic processes and time of drug intake [46]. Recognizing these variables, the 
establishment of method-specific, administrative cut-off concentration values is often 
employed in urine drug testing to aid the interpretation of results and decision-making [47]. 
 




Quantification of drug metabolites can provide conclusive information in forensic casework. 
For instance, the metabolite to parent drug concentration ratio has provided valuable 
information in the interpretation of forensic or clinical toxicology cases, including the 
estimation of timing of single-dose drug intake [48], investigation of adherence to treatment 
[49], determination of recent alcohol consumption [50], distinguishing between heroin and 
codeine use among individuals arrested for driving under the influence of drugs cases [51] or 
investigation of the manner of death due to acute drug toxicity [32, 52]. Beyond forensic 
sciences, quantitative metabolomic profiling is regarded as a promising approach to identify 
phenotypic changes in an organism, which could be used to study molecular mechanisms of 
various diseases and enable the development of prognostic and diagnostic tests based on 
specific patterns in metabolite levels [53, 54].  
2.2 NEW PSYCHOACTIVE SUBSTANCES (NPS) 
The NPS consist of diverse groups of substances that have been synthesized to mimic the 
anxiolytic, euphoric or addictive properties of illicit drugs. In a broad pharmacological 
sense, NPS can be categorized as depressants (including benzodiazepines, opioids and 
dissociatives), hallucinogens, stimulants, synthetic cannabinoids and “others” that do not 
clearly belong to any of the former groups. Some Internet vendors are typically openly 
marketing NPS with euphemisms, such as “legal highs” or “research chemicals”, referring to 
the fact that the new substances are intended to circumvent existing drug legislation. For 
practical reasons, the scientific literature is retaining the term NPS also for those NPS that 
are already under legislative control in some countries. Besides the legal or perceived legal 
status, the consumption of NPS is driven by other factors such as their ready availability, 
non-detectability in conventional drug tests, inexpensive dose price, perception of higher 
purity, and exciting user experience [55, 56]. Some NPS persist in the drug market even 
after legislative control [57], but many of these substances swiftly enter and exit the drug 
market, which leaves a minimal time-window for public health interventions. Healthcare and 
legislative response to NPS is challenging due to the high rate of emerging substances and 
their availability through the Internet. According to the UNODC, one or several NPS have 
been encountered already in 120 countries and territories with a total number of over 950 
substances by December 2019 [3]. On the EU drug market, the number of monitored NPS 
has already risen to over 730 substances [4]. Furthermore, the rate of newly reported 
substances sharply increased in the 2010s when 41 to 101 new substances were annually 
reported [4]. In recent years, a worrying phenomenon has emerged involving mislabeled 
NPS [58, 59]. NPS have also been used as cutting agents for traditional illicit drugs [60]. 
Such an activity has been frequently observed with stimulant-type NPS that have been sold 
as amphetamine or MDMA [61, 62], but also in cases where highly potent fentanyl analogs 
have been sold as heroin [63]. Especially in the latter case, the risk of fatal overdose is 
apparent due to misidentification and the difficulty of measuring an appropriate dose, both 
of which can lead to fatal respiratory depression [64-66]. These criminal actions might be 
explained on grounds of a better cost-efficiency or a lower risk of the product being detected 
in drug screening. 




The scarcity of information on the fundamental pharmacology and recreational and toxic 
concentration levels of NPS, combined with the obscurity of drug action due to polydrug 
use, makes evidence-based counter-measures difficult [67, 68]. Currently, only a small 
percentage of NPS have been studied under preclinical conditions, and even fewer have been 
tested on humans [69]. Furthermore, most of the available preclinical studies have been 
narrowly focused on the addictive potential, while a distinctively smaller number of studies 
are linked to chronic or acutely hazardous effects, such as cardiotoxicity, respiratory 
depression, neurological symptoms or hyperthermia [68]. In order to mitigate these harms, a 
responsive international collaboration system has been established. The EU Early Warning 
System, operated by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and Europol, plays a central role in supporting national and EU-level 
preparedness and responses to NPS. In operation since 1997, it comprises those two 
agencies, 30 national early warning systems across Europe, the European Medicines Agency 
and the European Commission. The Early Warning System is the first step in a three-step 
legal framework, additionally comprising risk assessment and legislative control [70, 71]. 
The purpose of the EU Early Warning System is to enable rapid information exchange on 
detection, prevalence and harmfulness of emerging NPS between the EU member states, as 
well as Norway, Turkey and United Kingdom.  
Forensic laboratory analysis plays a central role in getting off to a good start in 
understanding the epidemiology and toxicology of NPS. However, a recent report by the 
EMCDDA points out that laboratories continue to struggle with the analytical testing of NPS 
because of the unavailability of certified or otherwise reliable reference standards [72]. 
Therefore it has become evident that the transient nature of NPS and their fluctuation on the 
illicit drug market are hampering both legislative and scientific responses that are related to 
emerging NPS [73]. In general, access to these standards is hindered by multiple time-
consuming steps that should be completed before an analytically valid laboratory method 
can be put into operation (Figure 1). Initially, a sample of the suspected NPS should be 
acquired, followed by structural elucidation using advanced laboratory techniques, such as 
nuclear magnetic resonance spectroscopy (NMR) and HRMS [74]. Next, the structural 
information on the NPS released by the EMCDDA Early Warning System network can be 
used for early tentative detection by HRMS, until PRS are commercially available.  
 
 





Figure 1. Time-course for the development of analytical testing of NPS.  
2.2.1 STIMULANTS 
 
Stimulants are globally the largest group of NPS, as they represent approximately 36% of all 
NPS (December 2019) [3]. Since the rapid increase of reported NPS in the mid-2000s, some 
of the stimulant-type NPS have gained popularity as legal alternatives to the more 
established stimulants, such as amphetamine, methamphetamine, MDMA, or cocaine. 
Following this period, synthetic cathinones, sometimes marketed as “bath salts”, have 
become the most common stimulant-type NPS group, representing 39% of the overall NPS 
seizures in the EU in 2017 [4]. Synthetic cathinones are structural analogs of cathinone, a 
substance found in the khat plant (Catha edulis). As with other stimulants, they are 
commonly sold as powders and consumed orally or by snorting, but also injected 
intravenously [4]. Evidently, the emergence of various stimulant-type NPS has brought new 
problems, such as adulteration of the established illegal stimulants with synthetic cathinones 
[61] and fast-paced changes in the street drug composition.  
The main pharmacological mechanism of action of stimulant-type NPS is executed 
through the release of dopamine, noradrenaline and serotonin in varying levels. Typically 
desired stimulant effects are elevated alertness, wakefulness, concentration, and altered 
behavioral characteristics, such as euphoria, self-confidence and aggressiveness. Adverse 
effects include drug dependence, violent behavior, tachycardia, arrhythmia, kidney or liver 
failure, skin rashes, hypertension, hyperthermia, hallucinations, seizures and stroke [75, 76]. 
Structural classification of stimulant-type NPS is difficult because the members of this 
pharmacological class exhibit great structural diversity that may or may not have a 
resemblance to the more established drugs (Figure 2). Moreover, the aforementioned 
pharmacological properties of stimulant-type NPS overlap with other commonly 
encountered NPS classes, such as synthetic cannabinoids and hallucinogens.  






Figure 2. Structural classification of NPS stimulants and related established stimulants. 
Adapted from Miliano et al. 2016 [77].  
2.3 ANALYSIS OF NEW PSYCHOACTIVE SUBSTANCES 
WITHOUT PRIMARY REFERENCE STANDARDS 
(PRS) 
The term PRS refers to an authenticated, uniform material that is intended for use in 
specified chemical analysis, in which its properties are compared with those of the sample 
under examination. A PRS possesses a degree of purity usually of 99.5% or higher. 
Traditionally, validity is determined experimentally by measuring accuracy (proximity 
to the true value) and precision (consistency of repeated measurements). Traceability and 
uncertainty are more recently introduced concepts, increasingly emphasized in the quality 
assurance guidelines and certification requirements (e.g., ISO/IEC 17025) [78]. The 
metrological traceability is defined as the “property of a measurement result whereby the 
result can be related to a reference through a documented unbroken chain of calibrations, 
each contributing to the measurement uncertainty” (International Vocabulary of Metrology, 
2007) [79]. In essence, it describes the comparability of individual measurements in 
different laboratories or at other time points, which is determined by the degree of 
uncertainty at each step.  
Lack of PRS is an evident problem in the analysis of NPS and their metabolites, 
compromising the traceability of results. The rapid emergence of a large number of NPS and 
their short lifetime oblige forensic laboratories to acquire numerous new reference standards, 
preferably within the shortest time period possible. However, PRS are often expensive, and 




some of them do not even exist in the catalogs of commercial vendors. Some vendors offer 
custom synthesis services, however, these are even more costly and the acquisition of such 
material may take even 3 to 5 years [80]. Alternatively, NPS reference standards can be 
sought by gray-market sourcing (direct purchase from an NPS vendor) or by utilizing 
pharmaceutical impurities [81]. However, these type of material are not directly suitable for 
quantitative analysis, because the product content is not reliable and the purity can be either 
low or inconsistent.  
Presently, a combination of HRMS and NMR techniques is a favored strategy in the 
structural elucidation of unknown NPS, as these techniques can uncover highly specific 
chemical information about the substance in question (e.g., molecular composition, 
molecular structure, molecular mass, functional groups, connectivity of atoms) [74]. In 
addition, NMR can be used to estimate the purity of unknown drug material [74, 82]. 
Despite the merits of NMR in structure analysis, this thesis focuses on HRMS which is a 
more achievable technique with a capability for high-throughput analysis of complex 
biological specimens.  
2.3.1 HIGH-RESOLUTION MASS SPECTROMETRY (HRMS): 
IDENTIFICATION OF UNKNOWN SUBSTANCES 
 
Chromatographic and MS techniques have taken root in today’s clinical and forensic 
laboratories that analyze body fluids, tissues and seized material. Because of their 
sensitivity, selectivity and high-throughput capability, hyphenated MS techniques have 
become indispensable in drug analysis [83], increasingly surpassing immunoassay 
techniques [84, 85]. Both GC-MS and LC-MS are capable of producing a vast amount of 
information in a single analysis, which makes these techniques ideal for the fast and 
comprehensive screening of hundreds of drugs, metabolites and biomarkers. In MS, 
identification can be pursued with or without using a PRS. When reference standards are 
available, the experimentally determined properties of an analyte can be compared with the 
corresponding properties of a reference standard. Identification parameters, such as the 
retention time, isotopic pattern, monoisotopic mass of precursor ion, and spectral pattern can 
be stored in an in-house spectral library or database. In the absence of reference standards, 
readily available MS/MS libraries or databases can be used to identify target substances that 
are experimentally fragmented under similar analytical conditions. However, identification 
is less accurate, if external spectral libraries or databases are used under poorly matching 
conditions without retention time information. On the other hand, a mere knowledge of the 
molecular structure may be sufficient, when identification is based on the accurate mass 
measurement of the precursor ion, comparison to theoretical in silico mass spectra, or 
interpretation of molecular fragmentation by using rules and algorithms [86]. 
General unknown screening is considered one of the most challenging tasks in 
forensic laboratories, because the analyst has to develop generic analysis methods and mine 
complex MS/MS data sets. However, the initial detection of NPS is efficiently carried out 
using an analytical strategy known as “suspect screening”, in which the tentative 
identification is based on preliminary information on molecular formula to suggest 
substance identity [87-89]. The MS-based suspect screening approach has made progress 




over the last few decades, firstly because of the advances in HRMS, and secondly due to the 
emergence of a new data collection technique called data-independent acquisition (DIA). 
The advent of new HRMS analyzers has enabled fast, straightforward and affordable 
tentative substance identification, based on accurate (± 5 ppm) molecular mass 
measurement. Suspect screening is based on the fact that if the mass of an ion from a 
chemical compound is determined with sufficient accuracy, the elemental composition of 
that compound can be deduced. Low-resolution mass spectrometry (LRMS), on the other 
hand, is restricted to aid identification mainly based on fragmentation patterns. Unlike 
Fourier transform ion cyclotron resonance MS (FT-ICR), which is still recognized as the 
state-of-the-art technique in terms of mass accuracy and resolving power, current quadrupole 
time-of-flight MS (QTOFMS) and Orbitrap MS techniques are more suitable for routine 
analytical laboratories because of lower costs and more facile operation. High data 
acquisition speed is required in the hyphenated techniques to ensure the possibility of 
acquiring multiple data points across the chromatographic peak. The improved data 
acquisition in DIA enables the collection of precursor and fragment data by alternating the 
collision energies throughout the chromatographic separation, without predefining target 
molecules in the acquisition method. DIA was exploited already in 2001 in the context of 
target and suspect drug screening with use of a single stage LC-TOFMS instrument by 
Gergov et al. (2001) [90], and more recently, DIA based LC-QTOFMS has been 
increasingly applied to the early detection of drugs, NPS and metabolites in herbal blends 
[91] and biological samples [6, 92]. 
Evidently, HRMS together with DIA allow a better sensitivity and previously 
unavailable advantages in drug analysis, such as the tentative identification based on 
molecular formulae (elemental composition) and retrospective analysis. These features are 
certainly ideal in the suspect screening for NPS. In retrospective analysis, historical 
acquisition data is re-processed once new suspect information is obtained. For example, 
Noble et al. (2018) stored the HRMS data from 2339 blood samples and re-processed the 
original data against an updated database containing 50 fentanyl analogs [93].  
Identification of unknown substances by HRMS is facilitated by the availability of 
several online spectral libraries, as the acquired data can be searched against the spectral 
information that is provided by other investigators. Some examples of the existing free 
libraries or databases are MassBank [94], mzCloud [95], NPS Data Hub [96], and the 
recently emerged HighResNPS [97]. Interestingly, HighResNPS utilizes a database 
containing the diagnostic fragment ion instead of the whole spectrum. This feature promotes 
better inter-laboratory transferability, as the search results are less affected by different 
method variables and HRMS vendor platforms. A vast majority of the accurate mass –based 
spectral data commonly available has been collected using LC combined with ESI and 
HRMS, while comparable data by GC-APCI is lacking.  
2.3.2 SEMI-QUANTITATIVE MASS SPECTROMETRY 
 
Thus far, there have been no studies attempting to measure NPS in biological samples 
accurately in the absence of PRS or radiolabels. In semi-quantitative analysis, an 
approximation of the concentration is obtained by assuming that the ion response of a target 




substance is similar to a secondary calibrator. Overall, semi-quantitative analysis by MS can 
provide a quick approximation of analyte concentration that could be incredibly valuable in 
an early phase of research. This approach remains inaccurate because the ionization 
efficiency is sensitive to the analytical conditions, surrounding matrix, and analyte structure 
[7, 8, 98]. Furthermore, the extraction recovery cannot be determined in the absence of 
reference standards. However, according to Niwa et al. (2020), the role of extraction 
recovery is relatively insignificant when using a structurally similar secondary calibrator. In 
their report, approximately 86% of the measurement bias was attributed to the ionization 
response ratio, and only 14% was caused by a loss in the sample extraction stage [98].  
Despite the fact that the use of secondary calibrators attempt to minimize 
measurement bias, previous studies with LC-ESI-HRMS have shown that a gross error in 
quantitative estimation should be expected, if an equal signal response is assumed. In the 
study by Hatsis et al. (2017), the parent drugs were used as surrogates for the quantitative 
estimation of their metabolites. In their dataset of 45 parent drugs and metabolites prepared 
in a solvent, more than a half of the studied substances were quantified with over 2-fold 
error, the error being up to 71-fold in the worst case [8]. A bias of the same magnitude was 
found with Orbitrap and QTOFMS instrumentation in the study by Blanz et al. (2017), in 
which the measurement bias for 199 out of 233 (85%) measured metabolites ranged 20-
200%, while the rest of the metabolites were either outside this range or remained 
undetected [99]. Kruve et al. (2020) improved the quantitative estimation approximately by 
10-fold using an instrument-corrected ionization prediction model, in which predictions 
were made based on analyte structure and solvent composition. Using this in silico model, a 
5.4-fold mean measurement bias was obtained for a set of 31 substances that were spiked 
into blank oat, barley, rye, wheat, rice and maize [100]. The use of LC-nanospray ionization 
MS has been a promising improvement towards uniform response, because it exhibits a 
higher tolerance to salts and shows a better ionization efficiency than the conventional ESI, 
reducing the overall bias of the ionization process [101]. Nanospray was used by Valaskovic 
et al. (2006) for the quantitative estimation of the well-known drug metabolites of codeine, 
dextromethorphan, tolbutamide, phenobarbital, cocaine and morphine. All metabolites were 
measured accurately without PRS (20% bias), when parent drugs were used as secondary 
calibrators [102]. However, less satisfactory data were obtained in the comprehensive study 
by Schadt et al. (2011), in which 73 metabolites in various matrices were quantified using 
the corresponding parent drug as a secondary calibrator [103]. In this study, 86% of the 
metabolites could be measured within a 300% bias range. Clearly, these semi-quantitative 
estimations fall short of the guidelines used in forensic toxicology, where usually only a 
20% bias is tolerated in the basic method validation [104].  
2.3.3 NITROGEN CHEMILUMINESCENCE DETECTION (NCD) 
 
The NCD is one of the most viable detectors for the quantitative analysis of drugs without 
PRS, because it possesses an equimolar response to nitrogen [105]. When combined with 
LC, the technique has been referred to as chemiluminescence nitrogen detection (LC-
CLND). Although other universal (or near-universal) detection approaches exist, including 
the LC-coupled refractive index detector (LC-RID), evaporative light scattering detector 




(LC-ELSD), and charged aerosol detector (LC-CAD), as well as the GC-coupled vacuum 
ultraviolet detector (GC-VUV), flame ionization detector (GC-FID), these techniques have 
shown very restricted use in the analysis of biological samples due to their limited sensitivity 
or limited capacity to analyze complex material, as reviewed by Zhang et al. (2019) [106]. 
Quantitative NMR stands out because it allows accurate and precise quantitative estimation 
without requiring an isolation procedure [107]. The problems encountered in the past, 
including poor linearity, stability and sensitivity, are significantly improved with modern 
NMR instruments [106]. However, occasional data loss caused by overlapping resonances 
and the complexity of data analysis may still limit its broader application to the analysis of 
biological matrices [107, 108]. 
Many known small molecules, such as vitamins, nucleic acids, natural alkaloids and 
drugs, contain nitrogen atoms in their structure and exhibit biological activity or 
pharmacologically interesting properties [109]. According to a database of MDL 
Information Systems, approximately 90% of pharmaceutical drugs contain nitrogen [110], 
making NCD an attractive option for drug analysis. Major drugs of abuse that do not contain 
nitrogen are few; they include gamma-hydroxybutyrate, natural and many synthetic 
cannabinoids, as well as most anabolic steroids. Quantification by NCD is based on the 
chemiluminescence reaction, in which the measured signal is an emission that is released 
after nitrogen compounds are oxidized to nitric oxide and subsequently reacted with ozone 
in the gas phase (detailed operating principle in Figure 3) [111]. The emitted 
chemiluminescence has a high linear range and is equimolar to nitrogen [105]. According to 
the manufacturer’s specifications, a commercial GC-NCD instrument has a favorable 
linearity (>104), sensitivity (LOD < 3 pg nitrogen/s) and selectivity over carbon signal (> 
2x10 7 response N / response C) [112]. This mechanism essentially differs from the nitrogen-
phosphorus detector (NPD), in which the signal correlates with the number of produced ions 
[113]. More specifically, NCD is not a universal detector, because minor structure-
dependent response have been observed. However, only a 10-15% variation has been 
reported in all cases, except when two nitrogen atoms are adjacent to each other [114].  
 
 





Figure 3. Schematic diagram of gas chromatography - nitrogen chemiluminescence 
detection (GC-NCD). The GC effluent is directed to the burner (1), where in the presence of 
oxygen at a high temperature (900 ℃), organic molecules are combusted to various oxides 
and water. Nitric oxide is transferred to the reaction cell (2), where it is mixed with ozone 
(O3) in order to produce nitrogen dioxide in its excited state (NO2*). Next, nitrogen dioxide 
returns to the ground state with the emission of photons. The resulting photocurrent is 
amplified in the photomultiplier tube (PMT) and detected. The Figure was adapted from 
Agilent 255 NCD Operation and Maintenance Manual (2012) [112].  
 
Prior to 1980’s, commercial standalone NCD instruments were mainly applied to 
environmental analysis [115, 116], but a leap towards drug and bioanalysis was taken upon 
the appearance of hyphenated GC-NCD in 1980 [117], and later with LC in 1988 [118]. In 
their analysis of dried tobacco samples, Cai et al. (2012) [119] pointed out that GC-NCD 
exhibited a superior precision, stability and peak shape over GC-NPD. The investigation of 
eight tobacco alkaloids in five replicate injections (0.5 µg/mL) showed that the CV was 
generally lower by GC-NCD (<0.5%) than by GC-NPD (<3.2%), possibly because of the 
NPD’s susceptibility to solvent interferences and bead aging. It was also mentioned that one 
alkaloid could be used to quantify the others by using the N-equimolar principle, which 
could significantly simplify the experimental set-up. Based on LC-CLND, the N-equimolar 
response has been used in a range of applications to determine the purity and quantity of 
small molecule drugs and organic compounds. Fitch et al. (1997) proposed the use of LC-
CLND for the determination of the yield and purity of synthesis products [120], and this idea 
was later applied by Yan et al. (2003) [121] and Letot et al. (2005) [122] to combinatorial 
chemistry libraries using caffeine and diphenhydramine, respectively, as external secondary 
calibrators. Thomas et al. (2016) applied LC-CLND to estimate the purity of several toxin 
reference standards using caffeine as an external secondary calibrator. In that study, the 




purity of seven structurally diverse natural toxins was measured with an impressive accuracy 
of 97-102% and a high precision (CV 2%) [123]. 
Apart from the articles I-V included in this thesis, N-equimolar quantification of NPS 
by NCD/CLND has been published only in three other papers, all of which focused on the 
analysis of drugs seized by the Finnish police or Customs, using an LC-CLND instrument 
and caffeine as an external calibrator. In the first paper, published by Laks et al. (2004) [9], 
21 seized samples, containing mostly commonly abused drugs (e.g., amphetamine, cocaine 
and heroin) and some tryptamine-derived NPS, were analyzed. In total, 11 individual 
substances were quantified by LC-CLND and the results were compared to a reference 
method. The mean difference compared to the reference method was 11% (range 4-21%) 
and imprecision (CV) was 6%. Ten years later, the LC-CLND approach was applied by 
Rasanen et al. (2014) to 61 previously identified NPS in 177 seized powders or herbal 
products, containing mostly stimulants/hallucinogens and synthetic cannabinoids. In that 
study, the method performance was tested using 16 NPS with known purity, resulting in 
95% mean accuracy (range 83-105%) and 13% mean expanded uncertainty of measurement 
[124]. In the third paper, Rasanen et al. (2019) applied LC-CLND to the purity analysis of 
seized samples containing furanylfentanyl (N = 112), carfentanil (N = 98) and U-47700 (N = 
7). In that study, the method performance was tested using 11 synthetic opioids, resulting in 
96% mean accuracy (range 91-101%) [125].  
Apart from the articles I and III-V included in this thesis, only three papers can be 
found in the scientific literature that apply quantitative LC-CLND analysis without PRS to 
body fluids. The study published by Deng et al. (2004), using dog urine and plasma, and the 
study by Ojanperä et al. (2007), using human plasma, were proof of concept -type studies 
determining the metabolite to parent drug concentration ratios with a simulated assumption 
that PRS for the metabolites were not available [126, 127]. In the third paper by Ojanperä et 
al. (2007), 33 drugs spiked in plasma and blood were quantified after liquid-liquid extraction 
(LLE) with n-butyl chloride - isopropanol (98 + 2) at a basic pH [128]. The mean bias in 
plasma and blood was 24% and 17%, respectively, and the highest bias in either matrix was 
31%.  
It is noteworthy that, prior to the present thesis, GC-NCD was neither applied to 
analytical problems related to NPS nor the combination of HRMS and NCD for 
simultaneous identification and quantification was explored. In particular, this thesis 
presents pioneering studies on the use of NCD hyphenated with GC, rather than LC, in N-
equimolar drug analysis. Obviously, the GC-NCD-APCI-QTOFMS platform will expand the 
scope of the previously presented approach by enabling identification and quantitative 










3 AIMS OF THE STUDY 
The aim of the thesis was to develop and validate a new analytical approach for instant 
simultaneous identification and quantification of suspected NPS in biological samples and in 
seized material, by using secondary quantitative calibrators to simulate conditions where 
PRS are not accessible.  
 
The specific aims of each article were as follows: 
 
• To describe the new GC-NCD-APCI-QTOFMS approach and verify its 
performance in drug analysis under preliminary experimental conditions using 
sheep blood (I). 
 
• To elaborate accurate mass -based monitoring of suspect NPS and the usability of 
external drug databases by employing the GC-APCI interface (II). 
 
• To develop and evaluate a quantitative analytical method for the investigation of the 
urinary metabolism of the stimulant-NPS alpha-pyrrolidinopentiophenone (α-PVP) 
using the GC-NCD-APCI-QTOFMS approach (III). 
 
• To develop and evaluate a generic quantitative analytical method for NPS-
stimulants in blood samples using the GC-NCD-APCI-QTOFMS approach (IV). 
 
• To develop and evaluate a generic quantitative analytical method for NPS-
stimulants in seized powdery material using the GC-NCD-APCI-QTOFMS 
approach (V). 
 




4 MATERIALS AND METHODS 
This chapter briefly describes the procedures of this work. More detailed descriptions are 
found in the original articles (I-V). 
4.1 MATERIALS 
4.1.1 REFERENCE STANDARDS AND SEIZED DRUGS 
 
All PRS were obtained from various pharmaceutical companies and were of pharmaceutical 
purity. The seized material used in II and V were obtained from the Finnish law 
enforcement authorities (National Bureau of Investigation and Customs Laboratory).  
4.1.2 SAMPLE MATERIAL 
 
All post-mortem blood (IV) and urine samples (III) were collected by the forensic 
pathologists of the Finnish Institute for Health and Welfare (Helsinki, Finland). Individual 
blood (IV) and urine (III) samples from living persons were given by healthy volunteers. 
Pooled blood (IV) from living persons was acquired from the Finnish Red Cross Blood 
Service (Helsinki, Finland). Sheep blood (I) was purchased from Bio Karjalohja Oy 
(Karjalohja, Finland). All blood and urine samples were stored at 4ºC in preserved tubes 
containing 1% of sodium fluoride. 
4.1.3 DERIVATIZATION REAGENTS 
The derivatization reagents MBTFA (N-methyl-bis-trifluoroacetamide) (V) and MSTFA (N-
methyl-N-(trimethylsilyl)trifluoroacetamide) with 1% TMCS (trimethylchlorosilane) (III) 
were purchased from Thermo Fisher Scientific (Bellefonte, PA, USA), and TFAA 
(trifluoroacetic anhydride) (IV) was from Sigma-Aldrich (Steinheim, Germany). 
4.2 SAMPLE PREPARATION 
4.2.1 SOLUTIONS 
 
Each reference standard was dissolved in methanol (I-V) or in a chloroform/pyridine (5:1) 
mixture (V) to obtain a 1 mg/mL stock solution. Thereafter, the stock solution was further 
diluted to obtain appropriate working solutions. Some of the reference standards and seized 
materials were analyzed directly after dissolution (II and V) or after derivatization (V).  




4.2.2 LIQUID-LIQUID EXTRACTION (LLE) 
 
All blood and urine samples were extracted by LLE prior to GC-NCD-APCI-QTOFMS 
analysis under basic conditions. Briefly, the samples were basified with Tris buffer (pH 11) 
in I and III, and urine samples were additionally treated with 1M NaOH. In IV, 5% 
ammonium hydroxide was used. Subsequently, samples were mixed with an appropriate 
extraction solvent, involving butyl acetate (I) or butyl chloride/ethyl acetate in volumetric 
ratios of 1:3 (III) and 3:1 (IV). Additionally, 0.03 g of NaCl was added to assist the transfer 
of analytes into the organic phase in IV. After centrifugation, the organic phase was 




In III, an aliquot of the organic phase was mixed with 40 µL of MSTFA + 1 % TMCS 
silylation reagent and incubated for 15 min at 50 ℃. In IV, an aliquot of the organic phase 
was mixed with 15 µL of TFAA acylation reagent and incubated for 15 min at 50 ℃. After 
cooling, the mixture was neutralized with 700 µL of NaHCO3, centrifuged, and the organic 
phase was collected for subsequent analysis. In V, an aliquot of the organic phase was mixed 
with 50 µL of MBTFA acylation reagent and incubated for 30 min at 70 ℃. 
4.3 METHODS 
4.3.1 CONFIGURATION OF THE GC-NCD-APCI-QTOFMS PLATFORM 
 
A 7890B Series GC System equipped with a 7693 Automatic Liquid Sampler and a 
split/splitless injector was coupled through a G3180B Two-Way Splitter with Makeup Gas 
(He) to an APCI 6540 UHD Accurate-Mass QTOF mass analyzer and a 255 Nitrogen 
Chemiluminescence Detector (all Agilent Technologies, Santa Clara, CA). The 
configuration and operating principle are briefly illustrated in Figure 4. 
 
 
















4.3.2 GAS CHROMATOGRAPHY (GC) 
 
The injector liner was a Single taper Ultra Inert liner with glass wool (Agilent 5190-2293). 
The analytical column was a DB-5MS (30 m × 0.25 mm id with 0.1 µm film) capillary 
column (Agilent Technologies). After the analytical column, the GC flow was divided 
between the NCD and the APCI ion source through a two-way splitter, using 0.55 m x 0.18 
mm and 2 m x 0.18 mm uncoated deactivated fused-silica post-columns to obtain a 10:1 
flow ratio, respectively. The splitter pressure was 15.8 psi and the flow ratio was calculated 
using the Effluent Splitter Calculator (with Makeup) (Agilent Technologies). In this 
concurrent detection, the NCD signal arose 0.02 minutes earlier than that of QTOFMS.  In I-
IV, the GC was operated in the pulsed splitless injection mode with an equilibrium time of 
0.75 min and 50 mL/min purge flow to split vent at 0.75 min. A pulse pressure of 50 psi was 
applied prior to using initial head pressure of 24.9 psi. In V, split injection mode was used at 
a ratio of 10:1. The injector port temperature was 250°C and transfer line temperature 
320°C. The injection volume ranged from 1 to 5 µL, depending on the application. In I-IV, 
the oven temperature was initially held at 100°C for 0.5-0.75 min and then increased by 
30°C per min to 320°C, which was held for 6 min. In V, the oven temperature was initially 
held at 80°C and then increased by 30°C per min to 280°C and at the rate of 10°C per min to 
320°C, which was held for 4 min.  
4.3.3 QUADRUPOLE TIME-OF-FLIGHT MASS SPECTROMETRY 
(QTOFMS) 
 
The QTOFMS was operated in the APCI positive ionization mode, with the drying gas 
(nitrogen) flow at 5.0 L/min and gas temperature at 365 °C. The current of the corona 
discharge needle was 1000 nA and capillary voltage 1000 V. The fragmentor voltage was 
140 V (II-V) or 150 V (I) and skimmer voltage 65 V. In I and II, the mass acquisition was 
performed in the targeted MS/MS mode, and in III-V, in the all ions mode (DIA) in which 
collision energy ramps from 0 eV (low energy function) to 10-22 eV (high energy function) 
were used. The data was acquired at an m/z range of 50-500 with an acquisition rate of 5 
spectra/s. External mass calibration was carried out using the ESI or APCI tuning mix 
(Agilent Technologies). The ion m/z 257.2475 was used for internal calibration throughout 
the chromatographic separation. The QTOFMS was operated in 2 GHz, Extended Dynamic 
Range mode. The identification criteria were as follows: the maximum mass error for 
precursor and product ion was set at 1-2 mDa. In III and IV, the retention time tolerance 
was set at 0.1 and 0.02 min, respectively. In IV, the intensity threshold was set at 10 000 
counts for the precursor ion and 1000 counts for the product ion. The target mass of the 
precursor ion was based on the accurate mass of the protonated precursor ion or its acyl or 
trimethylsilyl derivative with an increased mass of 95.9823 or 72.0396 Da, respectively. The 
GC-NCD-APCI-QTOFMS spectral library used in II was based on averaged spectra over 12 
intra-day measurements. The library scoring system algorithm used a reversed search query 
which included monoisotopic mass, relative abundances and isotope spacing to give a score 
that scaled from 0 (no match) to 100 (identical match). Data acquisition and processing were 
performed with the MassHunter Data Acquisition B.04.00, MassHunter Profinder B.06.00, 




MassHunter Personal Compound Database and Library Manager B.07.00 and MassHunter 
Qualitative analysis B.07.00 software (all Agilent Technologies). The GC-APCI-QTOFMS 
in-house library (II) was created using a high sample concentration (5 µg/mL) to ensure that 
even the polar substances could be detected. In IV, the relative ion response compared to a 
secondary calibrator was obtained by comparing the slope values with two calibration points 
(0.05 and 0.25 µg/mL).   
4.3.4 NITROGEN CHEMILUMINESCENCE DETECTION 
 
Pyrolysis of the analytes in the NCD was carried out at 900 °C under a hydrogen flow rate of 
4 ml/min and an oxygen flow rate of 9.4 ml/min. Data from the NCD was collected at 50 Hz 
over the entire course of the analysis. OpenLab CDS Chemstation GC driver A.02.05.021 
was used to control the GC-NCD. In quantitative estimation, a linear regression model was 
constructed with an appropriate external calibrator. The peak area was corrected according 
to the relative nitrogen content prior to applying the linear regression model. All peak areas 
were normalized to the peak area of the internal standard, which was either dibenzepin-d3 
(I-II) or buspirone (IV-V). 
4.3.5 LIQUID CHROMATOGRAPHY – CHEMILUMINESCENCE 
NITROGEN DETECTION (LC-CLND) 
 
Purity estimation of seized material (V) was complementarily investigated by the LC-CLND 
technique, equipped with an ultraviolet diode array detector (UV-DAD), using caffeine as an 
external calibrator [124]. The LC was an 1100 series system instrument, equipped with an 
autosampler, a binary pump, a column oven, a 1260 infinity degasser, and a 1260 Infinity 
UV-DAD (all Agilent Technologies). The CLND was an Antek (PAC, Houston, TX, USA) 
8060 model, which was coupled in series after UV-DAD. The LC separation was performed 
in a gradient mode at 40 ℃, using 0.1% formic acid and methanol as mobile phase. The flow 
rate was 0.25 mL/min and injection volume was 10 µL. The proportion of methanol was 
increased from 10% to 90% over 15 min and held at 90% for 4 min. The post-time was 9 
min. Caffeine calibration standards were prepared by diluting with 0.1% formic acid: 
methanol 90:10 (v/v) to obtain caffeine concentrations of 1.0, 2.0, 3.0, 4.0, 5.0, 10, 20, 30, 
40 and 50 µg/mL which were equivalent to 2.9-144 ng of nitrogen per injection.  
 
 




5 RESULTS AND DISCUSSION 
5.1 GENERAL WORK-FLOW 
The GC-NCD-APCI-QTOFMS platform was designed to enable the monitoring and 
quantification of suspect NPS with acceptable accuracy in the absence of PRS. Figure 5 




Figure 5. Summary of the topics of articles I-V and related sample preparation methods. 
 
In the GC-NCD-APCI-QTOFMS workflow, a list of targeted monoisotopic masses was 
created based on the molecular formula of the protonated precursor ion [M+H]+, taking into 
account the mass increase resulting from derivatization. For example, the precursor ion of 
pentedrone has a formula of C12H17NO which corresponds to C14H16NO2F3 + H+ after 
protonation and derivatization by MBTFA (Figure 6).   





Figure 6. Acylation of pentedrone by MBTFA, resulting in mass increase from 192.1383 Da 
to 288.1206 Da (+95.9823 Da). 
 
After instrumental analysis, three separate windows were monitored: 1) Extracted ion 
chromatogram of library/database search for tentative identification, 2) NCD chromatogram 
for quantification, and 3) MS/MS in DIA for detailed structural analysis or retrospective 
identification (Figure 7). Since separation is performed by one GC instrument, the retention 
time connects the information obtained from the two detectors, NCD and APCI-QTOFMS. 









Figure 7. Visual analysis windows of GC-NCD-APCI-QTOFMS in the measurement of 
monoacylated pentedrone. Tentative identification was accomplished by finding the 
expected mass of the precursor ion in the extracted ion chromatogram (upper left). Constant 
acquisition of MS/MS spectra in DIA (below) at specific collision energies allowed the 
acquisition of structural information without pre-experiment targeting. Lastly, the qualitative 
MS results were combined with the GC-NCD quantification results (upper right) using the 
matching retention times.  
5.2 DERIVATIZATION 
Derivatization was used to increase the volatility of polar substances and prevent their 
decomposition and adsorption into the GC system [129, 130]. To ensure both qualitative and 
quantitative accuracy, the urinary α-PVP metabolites were silylated (III), and the parent 
stimulant-type NPS were acylated (IV-V). Trimethylsilylation by MSTFA produced a 
consistent peak shape for the hydroxyl (M1) and amino (M5) metabolites of α-PVP, which 
initially showed distorted peak shapes. However, MSTFA and trimethylsilyl (TMS) 
derivatives are sensitive to residual moisture that may lead to undesirable hydrolysis of 
reaction products. Hence, acylation was preferred in cases where only primary and 
secondary amines were targeted. TFAA was used in IV, but in V it was replaced with 
MBTFA to adhere to the adapted sample preparation procedure for seized powders [131]. 
Moreover, unlike TFAA, derivatization by MBTFA is more straightforward since its by-
product N-methyltrifluoroacetamide is a volatile and neutral compound which can be readily 




injected into the GC column [130]. General equations for the derivatization reactions used in 
this study are shown below: 
 
Trimethylsilylation of alcohols and amines with MSTFA 
 
R-OH + (CH3)3Si-X → R-O-Si(CH3)3 + HX  
R-NH + (CH3)3Si-X → R-N-Si(CH3)3 + HX  
 
Acylation of amines with MBTFA or TFAA 
 
R-NH + COCF3-X → R-N-COCF3 + HX  
 
Before quantitative analysis, the derivatization efficiency was studied by searching the 
extracted ion chromatograms for the underivatized precursor ion together with the respective 
derivatization product. Consequently, in addition to the two α-PVP metabolites that were 
successfully trimethylsilylated, 21 primary amines and 48 secondary amines were acylated 
with TFAA in the blood (IV) or by MBTFA in the powdered material (V). From these 
amines, only methoxetamine and 5-MeO-MIPT were not fully derivatized. In case of 
methoxetamine, it is likely that steric hindrance prevented the reaction from going to 
completion. Following this observation, incomplete derivatization of methoxetamine has 
also been reported after acetylation [132]. The secondary amino group of 5-MeO-MIPT is a 
part of indole moiety and difficult to derivatize with MBTFA. Nevertheless, both 
methoxetamine and 5-MeO-MIPT retained an excellent peak shape after reanalysis in the 
absence of the acylation reagent.  
 
5.3 IDENTIFICATION 
5.3.1 ACCURATE MASS MEASUREMENT OF THE PRECURSOR ION 
 
In-source fragmentation of the precursor ion may obscure the process of tentative 
identification. This problem is especially relevant in GC, where EI is commonly used as an 
ion source. However, previous studies on endogenous metabolites, pesticides and organic 
pollutants have shown that GC with an APCI source retains the intact precursor ion, and 
consequently GC could be coupled with HRMS for accurate tentative identification similarly 
to LC-ESI-HRMS techniques [133-135]. In the evaluation of the present GC-NCD-APCI-
QTOFMS platform, one important objective was to verify these observations before carrying 
out subsequent quantitative studies in I and III-V. In all of these articles, the maximum mass 
error was set at 1-2 mDa, which enabled successful tentative identification of all the studied 
substances. However, accurate mass alone is still prone to false-positive identification when 
isomeric substances with the same mass are encountered. A more comprehensive analysis of 
the acquired spectral data could reduce the number of false-positive identifications. Such 
approaches include isotopic pattern matching [136], limitation of the number of elements 




[136], retention time prediction [137], and in silico fragmentation algorithms [138-141]. 
However, these strategies were beyond the scope of this research. Furthermore, all NPS 
except the α-PVP metabolites in post-mortem urine (III) were previously confirmed by 
analysis with PRS. 
5.3.2 SPECTRAL LIBRARY AND DATABASE (II) 
 
Rapid detection procedures and toxicological risk assessment are needed to mitigate the 
harms of NPS [73, 81]. Online spectral libraries and databases increase the confidence of 
identification, because they contain useful information on the molecular formulae and 
fragmentation pattern [86]. However, these data have been primarily collected by using LC-
ESI-HRMS techniques instead of GC-APCI-HRMS. Lack of available online spectral 
libraries and databases specific to GC-APCI limits inter-laboratory collaboration within the 
scope of GC-NCD-APCI-QTOMFS. Article II aims to prove that online NPS databases 
created by LC-ESI-HRMS could be useful instead.   
Spectral libraries and databases offer an indispensable tool for screening of unknown 
compounds without PRS. A widely used library for GC-MS is the NIST/EPA/NIH Mass 
Spectral Library. Impressively, the 2020 version contains 350 643 low-resolution EI spectra 
from 306 869 chemical compounds [142]. On the other hand, GC libraries supporting the 
APCI source are unavailable despite the advantage of the combination in detecting the intact 
precursor ion. One explanation may be that construction, standardization and maintenance of 
high-quality spectral libraries and databases is not practical for less widespread techniques. 
Therefore, in silico generated databases could be used for tentative identification. A 
promising workflow for GC-APCI-QTOFMS was developed by Ruttkies et al. (2015). They 
used structures from chemical databases (KEGG and PubChem) to perform in silico 
derivatization prior to in silico fragmentation [143].    
According to the research hypothesis expressed in II, MS/MS spectra should be 
similar across different QTOFMS analyzers, regardless of the type of hyphened 
chromatography or ion source, assuming that the intact precursor ion is detected in sufficient 
abundance to produce consistent spectra. Hence the main difference between varying 
techniques lies in the ability to generate a sufficient abundance of intact precursor ions that 
will eventually reach the collision cell. To prove this hypothesis, the performance of a 
commercially available LC-ESI-HRMS library was compared to an in-house spectral library 
that was created by GC-NCD-APCI-QTOFMS, using the Agilent MassHunter Personal 
Compound Database and Library Manager software. In Figure 8, the spectral data for 29 
drugs of abuse was used to evaluate the similarity of these two libraries based on the 
following four criteria; 1) “Major fragments”: detection of five most abundant fragments in 
both libraries, 2) “Fragmentation pattern”: absence of unique fragmentation products, 3) 
“Library score”: manufacturer’s scoring system for library identification, and 4) “Fragment 
ion ratios”: similar ion ratios for three of the most abundant fragments. 
 
 





Figure 8. Comparison of GC-APCI-QTOFMS and LC-ESI-QTOMFS libraries containing 
29 drugs of abuse using four evaluation criteria. The figure was reconstructed using MS/MS 
data from II. On the right panel, the substances are listed together with their optimal 
collision energies (in brackets) used in the study. 
 
In this evaluation, the detection of major fragments (criterion 1) and the dissimilarities of 
fragmentation pattern (criterion 2) are both showing high acceptance rates for these criteria, 
with 29/29 (100 %) of the substances passing the criterion 1 and 27/29 (93.1 %) passing the 
criterion 2. These two criteria describe similarities between the two libraries qualitatively, 
emphasizing the detection of peaks with the same identity. On the other hand, library score 
(criterion 3) and fragment ion ratio (criterion 4) are largely influenced by the fragment ions’ 
relative abundance, and consequently the passing rate by these criteria was much lower, 65.5 
and 62.1 %, respectively. These results suggest that identification by GC-NCD-APCI-
QTOFMS should be carried out using an HRMS database with diagnostic fragments instead 
of full mass spectral libraries. It is likely that identification by mass spectral libraries, in this 
case, is more prone to errors because the degree of molecular fragmentation and ionization is 












Quantification without PRS by GC-NCD using an external nitrogen-containing secondary 
calibrator was accomplished in four separate studies: investigation of NPS metabolites in 
urine (III), quantification of NPS in blood (I, IV), and purity estimation of NPS in seized 
powdery material (V).  
5.4.1 MATRIX INTERFERENCES 
 
Co-elution of a target analyte with matrix interferences can potentially result in an 
overestimation of analyte concentration in quantitative analysis by NCD, and therefore the 
blank matrix background should be carefully studied in both NCD and QTOFMS 
chromatograms. Consequently, subsequent examination of full-scan QTOFMS spectra 
allowed detection of possible interference in such occasions, where co-elution was not 
visible in the NCD chromatogram. Interferences deriving from endogenous substances were 
mainly observed in the NCD chromatograms from blood and urine samples. As expected, 
sample derivatization increased the number of interfering peaks, because it improved the 
volatility and detectability of minor nitrogenous matrix components. In general, the 
likelihood of interferences detected decreased in the following order based on the sample 
type and preparation: derivatized urine > derivatized blood > urine > blood > derivatized 
powdery material > powdery material. Fortunately, a large proportion of the components of 
background noise, including residues from the buffer and derivatization reagent, were 
eluting much earlier than typical drug molecules. Some of the quantitative NCD results were 
rejected because of proven interference based on the corresponding QTOFMS spectrum. 
These cases were always manually evaluated before quantitative analysis. In such an 
evaluation, the NCD chromatogram was inspected for peak shape abnormalities, and the 
major ions in the QTOFMS spectrum should only belong to the target analytes or known 
matrix components not interfering with the analysis of blank material. 
5.4.2 QUANTIFICATION OF α-PVP METABOLITES IN URINE (III) 
 
An earlier publication by Tyrkkö et al. (2013) identified seven candidate structures for the 
urinary metabolites of α-PVP, based on the findings from in vitro studies or in silico analysis 
[139]. The accurate mass of each of these seven metabolites was targeted in post-mortem 
human urine samples previously found positive for α-PVP, and all the seven metabolites 
were found by GC-APCI-QTOFMS (Figure 9). Subsequent to these initial findings, the PRS 
for the metabolites M1, M3, and M5 were purchased from a commercial vendor for 
quantitative confirmation analysis. 
 






Figure 9. GC-APCI-QTOFMS chromatogram from a post-mortem urine sample showing 
peaks with a matching accurate mass (± 1mDa) for α-PVP and its metabolites.  
 
Quantitative method validation experiments with spiked specimens showed that the 
between-day bias and imprecision were regularly below 27% and < 13% (CV), respectively, 
when quantification by GC-NCD was performed using the parent drug α-PVP as a 
secondary calibrator. However, using a similar strategy in APCI-QTOFMS, poor 
quantitative accuracy was obtained, especially in the determination of the hydroxyl group -
containing metabolite M1. By APCI-QTOFMS, the bias for M1 in the low-concentration 
point (0.25 µg/mL) was 60% and in the high-concentration point (1 µg/mL) 58%, as 
opposed to the better results by GC-NCD (24% and 25%, respectively). Although only three 
substances were tested, this results was consistent with the earlier observations on secondary 
calibrator -based quantification attempts by MS, suffering from structure specific ion 
response [8, 98].  
Table 2 shows that nearly all of the 20 post-mortem urine samples included in the 
study were found positive for the target metabolites, based on the monitoring of the 
respective protonated precursor ions with high mass accuracy. The metabolites M1 and M5 
reacted successfully with MSTFA forming TMS derivatives, as proven by a mass increase of 
72.0396 Da. However, some of the quantitative data could not be properly acquired due to 


















Table 2. Tentative identification and quantitative estimation of α-PVP and its metabolites in 
20 post-mortem urine samples by GC-NCD-APCI-QTOFMS. Successful quantitative 
estimation was based on three prerequisites; 1) the detection of protonated molecule in 
APCI-QTOFMS spectrum, 2) sufficient sensitivity of GC-NCD and 3) the absence of co-
eluting nitrogenous compounds in GC-NCD.  
 
Substance 













α-PVP 100% (20/20) 65% (13/20) 92% (12/13) 2.28 (0.3-8.04) 5.8 13 
M1 100% (20/20) 70% (14/20) 79% (11/14) 1.50 (0.18-5.18) b 26.9 8 
M3 95% (19/20) 37% (7/19) 29% (2/7) 0.54 (0.38-0.7) 9.9 2 
M5 85% (17/20) 0% (0/17) - - - - 
              
a Excluding samples below the limit of quantification (LOQ) level (16 pg/N, corresponding to approximately 0.25 
µg/mL of derivatized M1). 
b One result at 0.18 µg/mL was extrapolated below the lowest calibration point (0.25 µg/mL). 
5.4.3 QUANTIFICATION OF STIMULANTS IN BLOOD (I, IV) 
 
Introduction of the proof-of-principle for the GC-NCD-APCI-QTOFMS platform was 
presented in I, using sheep blood spiked with bupropion, 2-DPMP, mephedrone, methylone 
and naphyrone. In that study, the role of the extraction recovery was ignored by spiking the 
blood post-extraction. Article IV elaborated the concept in a more realistic experimental 
setting: 38 illicit psychostimulants spiked in blood were analyzed taking advance of the 
control of extraction recovery by secondary calibrators. Compared to urine, blood samples 
showed considerably less matrix interferences in the GC-NCD chromatogram. 
Consequently, the lack of interferences and the possibility to use a higher injection volume 
(5µL) improved the sensitivity of GC-NCD, resulting in a generic limit of quantification 
(LOQ) of 0.05 µg/mL.  
The 38 NPS stimulants were chosen for the method development experiments based 
on the availability of the corresponding PRS in the laboratory. Fortunately, this starting 
point resulted in a structurally diverse group of stimulants to be tested. The mean between-
day bias and imprecision at the LOQ level (0.05 µg/mL) by GC-NCD were as good as 19% 
and 16% (CV), respectively. The highest bias of 44.3% was obtained with PCP 
(phencyclidine). In the developed method, the matrix interferences prevented reliable 
quantification of MBDB and, additionally, prevented quantification of dibutylone and 
methylphenidate at the LOQ level. Hence, quantification of the interfered targets might 
require method adjustment, such as changing the GC column. As for APCI-QTOFMS, the 
mean bias was as high as 60%, while the highest bias was found with naphyrone (186%). 
Comparison of the quantitative performance between GC-NCD and APCI-QTOFMS is 
illustrated in Figure 10. The figure shows that a bias higher than 30%, as well as the extreme 
values, were much more frequent with APCI-QTOFMS (in 24 cases, bias of 31-186%) than 
with GC-NCD (in five cases, bias of 31-43%).  







Figure 10.  Measurement bias in the quantitative estimation of 35 stimulants spiked in blood 
by using a secondary calibrator. Three substances (MBDB, dibutylone and methylphenidate) 
were excluded due to matrix interferences in GC-NCD. The following secondary calibrators 
were used: amphetamine for prim. amines, MDMA for sec. amines, and MDPV for tert. 
amines. Blue columns represent actual quantitative measurements by GC-NCD at LOQ 
(0.05 µg/mL), and red columns represent the deviation of the ion response slope between the 
target analyte and secondary calibrator in APCI-QTOFMS.  
5.4.4 QUANTIFICATION OF STIMULANTS IN SEIZED POWDERS (V) 
 
Analysis of powdery drugs without PRS using the N-equimolar principle of LC-CLND was 
pioneered by Laks et al. (2004) [9]. However, prior to this thesis, a similar approach has not 
been exploited in the GC-NCD environment or in conjunction with HRMS, altough the 
approach would enable the examination of peak identity and the detection of possible co-
eluting interferences. In V, a method was developed and validated for 28 stimulant drugs 
using a sample preparation method amenable to GC analysis: the drugs were dissolved in 
chloroform/pyridine (5:1) solution, acylated with MBTFA, and measured over five separate 
experiments. The mean bias was as low as 12%, with only cocaine showing a bias higher 
than 30% (36.2%). In all samples, the imprecision was always below 10% (CV), with a 
mean value of 5.5%. Subsequently, 42 seized powders of unknown purity were quantified by 
using both the newly developed GC-NCD method and an established LC-CLND method 
[124] for comparison. The mean purity value difference between the methods was on 
average 8.1 percentage units (range 0.4-26.7 percentage units). Although the results were 
             Prim. amines                           Sec. amines                       Tert. amines              




mostly consistent, it is likely that some of the larger discrepancies arose from solubility 
differences (in LC-CLND methanol was used). As compared to the LC-CLND method by 
Laks et al. (2004) [9], in GC-NCD the sample preparation and data interpretation stages are 
less straightforward, since derivatization of polar analytes is required.  
5.4.5 COMPARISON OF DEVELOPED METHODS 
 
The results from method validation experiments show that the quantitative performance 
remained adequately consistent despite the fact that very different sample materials were 
tested. This can be observed in Figure 11, which shows the relationship of the quantitative 
accuracy and precision across the GC-NCD methods using the grand mean values (the mean 
of five or six between-day repeats across all concentration data points) from a total of 63 
individual analytes. Seized powders (V) were generally measured with a slightly better 
precision compared to extracted blood samples (IV) (mean CV 7.1% vs. mean CV 11.6%, 
respectively), presumably due to a simpler sample preparation procedure for the powdered 
samples. Accuracy remained consistent throughout the used concentration range in both 
studies: 92.5-97.8% for extracted blood samples with a concentration range of 0.05–1.25 
µg/mL (IV), and 87.9-90.9% for seized powders with a concentration range of 40-200 
µg/mL (V). Regrettably, I and III contained only five and three separate analytes, 
respectively, and therefore the interpretation is only directive. The largest measured 
underestimation was observed with naphyrone in blood (bias -59.0%), and the largest 
overestimation with cocaine in a seized powdery sample (bias +45.0%). The best sensitivity 
(LOD 0.05 µg/mL) was reached in IV, mainly due to the fact that the highest possible 















Figure 11. Comparison of quantitative estimations from the GC-NCD-APCI-QTOFMS 
studies of this thesis. The data points are the grand mean values obtained from all between-
day accuracy and precision values from five or six separate experiments across the whole 
concentration range of the method: seized powders, 40-200 µg/mL (V), urine, 0.25-1.00 








6 GENERAL DISCUSSION 
It is well known that laboratory analysis of NPS is obstructed by the lack of certified PRS 
[81]. Therefore, the goal of early detection and toxicological assessment, followed by 
effective allocation of resources, should be met with a strategy that is fit for the analytical 
problem. In this study, a new analytical platform is introduced to combat the problem of 
lacking PRS and to provide means for instant analysis of NPS.   
Already established, fast detection of NPS without PRS can be accomplished with an 
LC-ESI-HRMS instrument, typically a QTOFMS or an Orbitrap mass analyzer [97], with 
use of accurate mass –based spectral libraries or databases. However, until now, the 
acquisition of quantitative data has been ignored mainly because of the technical challenges 
of MS quantification (e.g., structure-dependent ion response), which often lead to a gross 
measurement bias if the corresponding PRS are not used [7, 8, 98]. Consequently, an 
uncertainty factor has been used for the establishment of threshold values for toxicological 
decision-making to avoid possible under- or overestimations in quantitative analysis. In 
essence, the uncertainty factor is based on the theoretical probability distribution of 
measurement bias, and it has already been proposed for specific applications, such as for the 
toxicological evaluation of drug metabolites [98] and for the characterization of extractables 
and leachables [144]. However, such an approach has only limited usability if the margin of 
error remains high. Instead, a viable strategy to improve quantitative estimation is to utilize a 
universal detector that possesses a uniform response regardless of the structural composition 
of the substance. The GC-NCD-APCI-QTOFMS platform developed in this thesis enables 
simultaneous quantitative analysis based on the NCD detector’s N-equimolar principle with 
use of secondary calibrators, which makes the technique almost universally valid in drug 
analysis. 
The number of publications applying NCD/CLND has been steadily growing across 
various disciplines, and many sample types have been examined, including fuels [145-147], 
bio-oils [148], water [149], plant extracts [119, 150], house dust [151], soil [152], food [153, 
154], whisky [155], latex products [156], urban aerosol [157], drugs [9, 124, 158, 159], 
organic compounds [110, 122] and blood [126, 128]. Interestingly, a multidetector approach 
has been used to create synergy in many analytical applications. For instance, Ochiai et al. 
(2012) utilized sulfur chemiluminescence detector (SCD) mainly to characterize sulfur 
substances in whisky, but they complemented their analysis with NCD to investigate the 
presence of nitrogen-containing substances. Jiang et al. (2015) introduced an LC-
MS/UV/CAD/CLND platform, in which the quantification of pharmaceuticals was carried 
out by both CAD and CLND. In effect, these two detectors provided complementary 
information, since CLND is limited to nitrogen-containing compounds and CAD is not 
suited for the analysis of volatile substances that do not form particles [158]. Although the 
profiling and total quantification of the nitrogen containing fraction has commonly been 
performed by NCD, the detector’s unique advantage of N-equimolar quantification without 
PRS has rarely been applied in published studies. This gap in knowledge may be due to the 






The combination of three main technical advances previously presented in analytical 
instrumentation has allowed the successful development of the present GC-NCD-APCI-
QTOFMS platform for NPS analysis. Firstly, the possibility to acquire full-scan spectra for 
tentative identification by HRMS; secondly, the possibility to detect an unfragmented 
protonated molecule by using the APCI ion source, instead of the highly fragmenting EI 
source; thirdly, the possibility to apply NCD in quantitative analysis based on its N-
equimolar principle. GC-APCI has only recently become available due to a better 
commercial availability of the technology. It is vital to emphasize that the pioneers of GC-
APCI-QTOFMS instrumentation [133-135] have encouraged the conceptualization of the 
present GC-NCD-APCI-QTOFMS platform. 
In comparison to some of the older studies utilizing stand-alone LC-CLND, such as 
the one by Ojanperä et al. (2007) [128], the GC-NCD peak width obtained in this thesis was 
much narrower for similar amounts of drugs in blood after LLE. This is due to the fact the 
LC-CLND instrument brand available (Antek 8060 CLND) did not support the higher 
resolution and narrower peaks associated with modern ultra-high performance LC 
(UHPLC). Consequently, the current GC-NCD version was capable of producing a better 
chromatographic resolution than was obtained in the older studies, which is invaluable in the 
analysis of complex mixtures. 
One of the most critical limitations of GC-NCD-APCI-QTOFMS is the sensitivity of 
NCD, which in the present studies has been approximately 0.05 µg/mL in blood analysis 
(IV), slightly depending on the relative nitrogen content of each drug. As such, the 
analytical platform is ideal for stimulant-type NPS, which are present in biological samples 
at higher concentrations than representatives of some other drug classes, such as fentanyls 
and synthetic cannabinoids [69]. One possibility to enhance the sensitivity would be to 
include a concentration step, involving the evaporation of extraction solvent, in the sample 
preparation step. However, evaporation to dryness was deliberately avoided here because of 
potential losses of volatile substances. In case of the α-PVP metabolites in III, the 
concentrations of the less abundant metabolites M3 and M5 were often below the LOQ in 
the post-mortem urine samples studied. The sensitivity of APCI-QTOFMS was always 
better than that of NCD for all of the studied NPS, which is why the LOD obtained was 
significantly better than the LOQ despite the fact that the sensitivity of APCI-QTOFMS was 
compromised by the uneven distribution of GC flow. In this configuration, only 1/10th of the 
injected flow was directed to APCI/-QTOFMS. 
Interestingly, the sensitivity of APCI-QTOFMS could be further improved by an 
infusion of water to the APCI source, which reportedly enhanced the signal intensity and 
reproducibility of protonated precursor ions [160]. The sensitivity may also be improved by 
derivatization, which in most cases enhances ionization efficiency in MS [161]. Although 
the selectivity of NCD was reasonable in all studies, it is possible that some future 
applications to the analysis of substances with concentrations close to the LOQ level might 
encounter problems with the signal to noise ratio. In such a case, the possibility to use two-
dimensional GC (GCxGC) should be considered to achieve better selectivity and sensitivity 
[162]. 
 
The introduction of a derivatization step causes potential uncertainties for analytics. For 





evaporation of some analytes or the derivatization reaction could be incomplete. For this 
reason, following derivatization a search must be conducted against all possible products, 
with or without adducts, for tentative identification. Additional complexity arises in data 
analysis, because existing spectral libraries containing also derivatized substances for soft 
ionization HRMS are uncommon. Clearly, LC based instrumentation has certain advantages 
over GC based instrumention, such as a wider range of analytes that can be measured 
without the need for derivatization. 
In this thesis, suspect screening was solely based on the accurate mass measurement 
by APCI-QTOFMS. This is generally considered insufficient for unambigious substance 
identification, the latter requiring additional information that could be mainly obtained from 
use of PRS. Attempts to improve tentative identification by other measures, such as by using 
isotopic patterns, in silico prediction of DIA fragments, or retention time and ion mobility 
drift times, should be elaborated in future applications. In the past, some concerns were 
raised by Pacchiorotta et al. (2013) about the lack of online resources for spectral libraries 
for GC-APCI, unlike for GC-EI or LC-ESI [163]. However, the results for 29 structurally 
diverse drugs (mostly NPS) in II show that the MS/MS spectra obtained by GC-APCI-
QTOFMS are similar to those included in commercial LC-ESI-QTOFMS libraries. The 
results further suggest that the use of reference databases relying on precursor and major 
fragment ions is preferable to the use of whole spectrum libraries because of the difficulty of 
obtaining sufficiently matching ion ratios between instruments. 
The results published for urine (III), blood (IV) and seized powders (V) show that the 
expected mean bias for quantitative analysis without PRS in extracted or dissolved samples 
is approximately 10%, and all substances in these studies could be measured below a two-
fold error. This is a significant improvement over the semi-quantitative analysis by MS, in 
which the estimation of accuracy is much more unpredictable and even up to a 71-fold error 
in quantitative estimation has been reported [8]. In III and IV, it was demonstrated that GC-
NCD-APCI-QTOFMS could be used to reveal concentrations of NPS and their metabolites 
while performing a drug screen.  It can be anticipated that some of the most potential NPS 
research applications by the present approach are within retrospective drug analysis, as 
retrospective quantification of practically any nitrogen-containing peak is possible. Of 
course, in this type of application, a secondary calibrator similar to the analyte should be 
used. Another interesting application, which is also extremely difficult to conduct without 
PRS, is the measurement of metabolite to parent drug concentration ratios of NPS. Such 
information could help identify potential cases of poisoning and reveal individual 
differences caused by the pharmacogenetic variation or modulation of metabolic enzymes. 
Overall, the possibility to acquire quantitative information without PRS opens doors 
for future research not only in forensic science but also in other disciplines outside of 
forensics, such as metabolomics, environmental testing and discovery of biomarkers. As a 
final remark, the utility of the presented platform was designed for fast tentative analysis, 
and therefore it does not exclude the necessity of using certified PRS for the final 
confirmation of initial measurements. For now, there are no officially accepted criteria for 




Determination of the concentration levels of drugs is one of the important tasks in evidence-
based forensic science and, especially related to the topic of this dissertation, in the 
estimation of drug use and toxicity in the cause-of-death investigation and in the purity 
estimation of seized drugs for juridical decision-making. Prior to this thesis, rapid analysis 
of emerging NPS has been difficult to carry out, because conventional MS techniques are 
almost exclusively ruled out due to the poor availability of the necessary PRS. The 
developed GC-NCD-APCI-QTOFMS platform, which was first introduced in I, was 
designed to meet this problem by enabling the identification and quantification of NPS from 
biological samples and seized material, without immediate access to PRS.  
The main concept behind the GC-NCD-APCI-QTOFMS platform was to combine the 
HRMS and NCD detection techniques following GC separation into one easily manageable 
entity that allows tentative identification based on the high mass accuracy of HRMS and 
quantitative evaluation based on the N-equimolar principle of NCD. It was proved in II that 
identification by GC-APCI-QTOFMS can be based on external spectral libraries and 
databases produced by conventional LC-ESI-MS/MS, which further supports the early 
detection of NPS using information gathered by forensic collaborators. 
In III-V, quantitative estimation was carried out using carefully chosen external 
nitrogen-containing secondary calibrators. Analysis of NPS in authentic forensic material, 
such as seized powders (V), post-mortem blood (IV) and urine (III), was carried out with a 
mean accuracy of 91.7% (range 59.0-145.0%) and imprecision of 9.5% (CV), based on the 
data that was obtained from 28 NPS in seized powders, 37 NPS in post-mortem blood and 
three NPS metabolites in post-mortem urine. The fact that all individual measurements were 
performed with less than a 2-fold error, the mean bias being less than 10% in complex 
biological matrices, is a significant improvement over semi-quantitative MS measurements, 
showing up to >70-fold error even with dissolved powders [8]. However, it is noteworthy 
that the relatively low sensitivity of GC-NCD and the necessity to derivatize polar 
compounds for GC might limit some of the future applications.   
In conclusion, the GC-NCD-APCI-QTOFMS platform allows rapid generic analysis 
of stimulant-type NPS without PRS and without method parameter adjustment for individual 
analytes. In comparison to other techniques that do not necessarily require PRS, such as LC-
nanospray mass spectrometry or quantitative NMR, the present approach stands out due to 
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